K3-SPG

01/01/2019 - "In this study, K3-SPG given with conventional influenza hemagglutinin (HA) split vaccine (K3-SPG HA) conferred protection against antigenically mismatched heterologous virus challenge. "

01/01/2017 - "In conclusion, these results indicated that the vaccination using K3-SPG may overcome tolerance even in patients with chronic HBV infection."
01/01/2019 - "Our results indicated that FcγR-mediated antibody responses induced by the HA antigen and K3-SPG adjuvant were important for potent protection against antigenically mismatched influenza virus infection. "

01/01/2018 - "K3-SPG was previously shown to act as a potent monoimmunotherapeutic agent against established tumors in mice in vivo. "
08/02/2016 - "However, it has not been investigated whether K3-SPG alone can act as an anti-cancer immunotherapeutic agent or not. "
06/01/2023 - "Combination therapy with K3-SPG and anti-GPC1 mAb or another antitumor mAb may represent a new cancer treatment option acting via ADCC."
01/01/2022 - "K3-SPG-ISV suppressed tumor growth more potently than K3-ISV or K3-SPG intravenous injections, prolonged survival, and enhanced the antitumor effect of CPIs. "
01/01/2018 - "Therefore, even in the absence of specific Ags, we show that K3-SPG has potent Ag-specific memory CTL response-boosting capabilities, highlighting its potential as a monoimmunotherapeutic agent for chronic infectious diseases and cancer."

08/02/2016 - "This anti-tumor effect of K3-SPG monotherapy was also confirmed by using various tumor models including pancreatic cancer peritoneal dissemination model. "

01/01/2022 - "I will present an overview of their current R&D taking place in this field, then describe our recent progress, particularly regarding CpG oligodeoxynucleotides (ODNs), such as K3, K3-SPG, and D35 as either vaccine adjuvants or mono-immunotherapeutic agents for tropical diseases including malaria and leishmaniasis."